Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3Urogenital Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Neoplasms by Site 1Neoplasms 1Genital Neoplasms, Male 1Genital Diseases, Male 1

Interventions

Pemetrexed 9Carboplatin 7pembrolizumab 6Cisplatin 6130-nm albumin-bound paclitaxel 6Paclitaxel 5Nivolumab 5Gemcitabine 5palbociclib 4napabucasin 4durvalumab 4Fulvestrant 4Bevacizumab 4ribociclib 3osimertinib 3abemaciclib 3Mitomycin 3Irinotecan 3Fluorouracil 3Drug Therapy 3Anastrozole 3Albumin-Bound Paclitaxel 3selpercatinib 2pralsetinib 2patritumab 2ficlatuzumab 2exemestane 2atezolizumab 2Watchful Waiting 2Trabectedin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms by Site × (225)Ac-PSMA-617 × Clear all
NCT04597411 2026-04-30

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Endocyte

Phase 1 Active not recruiting
101 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡